Effects of somatostatin analogs on glucose homeostasis in rats.

Schmid HA, Brueggen J

The Journal of endocrinology10 Oct 2011Cited by 53 (Europe PMC)

PMID21987782DOI10.1530/joe-11-0224PepBankPUB-21987782

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats, single-dose subcutaneous pasireotide acutely elevated plasma glucose.
In plain wordsIn rats, a single pasireotide injection increased blood sugar.
Peptide
Pasireotide
Outcome
IncreaseAcute plasma glucose
Study
ratn: not reported in source
rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
single dose · subcutaneousAs given in this study (rat).
Source sentences
Summary
Single-dose s.c. pasireotide acutely elevated plasma glucose, whereas single-dose s.c. octreotide had no or a small hypoglycemic effect.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination.
Report a problemFND-2198778201
02AnimalAnimal study (in vivo)Mechanism
In rats, pasireotide-associated glucose elevation was transient and showed tachyphylaxis with repeated or continuous administration.
In plain wordsIn rats, the blood sugar rise with pasireotide weakened with repeated or continuous treatment.
Peptide
Pasireotide
Outcome
DecreaseGlucose tachyphylaxis
Study
ratn: not reported in source
rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (rat).
Source sentences
Summary
Glucose elevation with s.c. pasireotide was transient with tachyphylaxis after repeated or continuous administration.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination.
Report a problemFND-2198778202
03AnimalAnimal study (in vivo)Mechanism
In rats, pasireotide inhibited insulin secretion similarly to octreotide.
In plain wordsIn rats, pasireotide and octreotide similarly reduced insulin secretion.
Peptide
Pasireotide
Outcome
No significant changeInsulin secretion
Study
ratn: not reported in source
rats
Comparator
octreotide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Pasireotide and octreotide caused similar inhibitory effects on insulin secretion, whereas pasireotide had a weaker inhibitory effect on glucagon secretion than octreotide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination.
Report a problemFND-2198778203
04AnimalAnimal study (in vivo)Mechanism
In rats, pasireotide inhibited glucagon secretion less strongly than octreotide.
In plain wordsIn rats, pasireotide reduced glucagon secretion less than octreotide.
Peptide
Pasireotide
Outcome
IncreaseGlucagon secretion
Study
ratn: not reported in source
rats
Comparator
octreotide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Pasireotide and octreotide caused similar inhibitory effects on insulin secretion, whereas pasireotide had a weaker inhibitory effect on glucagon secretion than octreotide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination.
Report a problemFND-2198778204
05AnimalAnimal study (in vivo)Mechanism
In rats, continuous pasireotide infusion produced only small and transient plasma glucose elevations.
In plain wordsIn rats, continuous pasireotide infusion caused small, temporary blood sugar increases.
Peptide
Pasireotide
Outcome
IncreaseGlucose during continuous infusion
Study
ratn: not reported in source
rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · continuous infusionAs given in this study (rat).
Source sentences
Summary
Continuous infusion of pasireotide or injection of pasireotide long-acting release (LAR) resulted in only small and transient elevations of plasma glucose.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination.
Report a problemFND-2198778205
06AnimalAnimal study (in vivo)Mechanism
In rats, pasireotide LAR injection produced only small and transient plasma glucose elevations.
In plain wordsIn rats, pasireotide LAR injection caused small, temporary blood sugar increases.
Peptide
Pasireotide
Outcome
IncreaseGlucose with LAR injection
Study
ratn: not reported in source
rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Continuous infusion of pasireotide or injection of pasireotide long-acting release (LAR) resulted in only small and transient elevations of plasma glucose.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of pasireotide and octreotide on blood glucose, insulin, and glucagon levels in rats were evaluated alone and in combination.
Report a problemFND-2198778206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnPhase 2NCT03053284

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Centern = 0est. Apr 2017 to est. Apr 2018

Congenital Hyperinsulinism · Insulinoma · Hyperinsulinism

Trial page ClinicalTrials.govUpdated 14 May 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.